Correlation between exosomal PD‑L1 and prognosis in patients with cancer: a systematic review and meta‑analysis

• Lijun Huang ^[2] ; Qiurong He ^[2] ; Liping Liu ^[2] ; Jie Huang ^[2] ; Fan Chang ^[1]
  1. [1] University of Electronic Science and Technology of China

     University of Electronic Science and Technology of China

     China

     
  2. [2] West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 3, 2025, págs. 1288-1298
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background The predictive role of exosomal programmed cell death ligand l (exoPD-L1) in prognosis has been studied extensively; however, there is still no consensus.

    Methods Three databases, including EMBASE, PubMed, and Web of Science, were searched through January 4, 2024. The pooled hazard ratios (HRs) with 95% confdence intervals (95%CIs) were used to identify the relationship between circulating exoPD-L1 and prognosis.

    Results 15 studies with 1091 patients with cancer were included in this statistical analysis. High exoPD-L1 level was correlated with shorter progression-free survival (PFS) (HR=2.58, 95% CI: 1.75–3.81) and overall survival (OS) (HR=1.61, 95% CI: 1.32–1.98). Meanwhile, we found that dynamic upregulation of circulating exoPD-L1 in the early stages of immunotherapy was a favorable factor for prognosis (PFS: HR=0.34, 95% CI: 0.23–0.51; OS: HR=0.21, 95% CI: 0.13–0.26).

    Conclusion Circulating exoPD-L1 may be a valuable prognostic indicator for patients with cancer and monitoring its changes in the early stages of immunotherapy might be used to predict tumor response and clinical outcome. This conclusion may not apply to superfcial tumors.